Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,827 articles
Anavex Life Lead Drug Targets Early Alzheimer's Cause - New Study Highlights
Anavex Life Sciences Corp. (NASDAQ:AVXL) on Friday announced that a new peer-reviewed study published by the University of California in Proceedings...
Unusual Machines, NuCana, Navigator Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Friday.
Shares of Unusual Machines Inc (NYSE:UMAC) fell...
📰
Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology's Annual Scientific Session
TUCSON, Ariz., March 20, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC, maker...
📰
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad...
📰
TMYTEK and Comtech Join Forces to Enable Ubiquitous Connectivity through Next Generation of Multi-Orbit Distributed SATCOM Network User Terminals
TAIPEI, March 20, 2026 /PRNewswire/ -- TMY Technology Inc. (TMYTEK) unveiled advanced user terminal solutions for next-generation satellite...
📰
Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology’s Annual Scientific Session
Poster presentation and conference exhibit will feature early preclinical data on the Company’s fully implantable, autoregulating artificial heart...
📰
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad...
📰
Is CRISPR Therapeutics Stock a Buy Now?
We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.
📰
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad...
📰
5 Companies At the Center of America's Rare-Earth Revival
FN Media Group Presents Oilprice.com Market Commentary NEW YORK, March 20, 2026 /PRNewswire/ -- Six companies are quietly rebuilding one of the most...
📰
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report...
📰
Is CRISPR Therapeutics Stock a Buy Now?
We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock...
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive...
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive...
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive...
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock...
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock...
UnitedHealth Group Incorporated $UNH Shares Bought by Davis Selected Advisers
Davis Selected Advisers grew its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 0.6% in the third quarter,...
UnitedHealth Group Incorporated $UNH Shares Bought by Davis Selected Advisers
Davis Selected Advisers grew its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 0.6% in the third quarter,...
UnitedHealth Group Incorporated $UNH Shares Bought by Davis Selected Advisers
Davis Selected Advisers grew its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 0.6% in the third quarter,...
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady...
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady...
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady...
Prestige Bets $1 Billion On World's Most Iconic Nasal Strip
Prestige Consumer Healthcare Inc. (NYSE:PBH) on Friday announced a definitive agreement to acquire the Breathe Right brand for $1.045 billion.
The...
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
Co-Diagnostics Inc. (NASDAQ:CODX) on Friday signed an agreement for CoSara Diagnostics Pvt. Ltd, to expand its commercial and distribution territory...
Here's Why You Should Add McKesson Stock to Your Portfolio Now
McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.
Here's Why You Should Add McKesson Stock to Your Portfolio Now
McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.
Here's Why You Should Add McKesson Stock to Your Portfolio Now
McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.
Here's Why You Should Add McKesson Stock to Your Portfolio Now
McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
SEC Under Bipartisan Pressure To Curb 'Opaque' Chinese Firms' Access To US Capital Markets
U.S. lawmakers have urged the Securities and Exchange Commission (SEC) to limit Chinese companies’ access to American capital markets, citing...
Super Micro Stock Hits 52-Week Low - Here's Why
Super Micro Computer Inc. (NASDAQ:SMCI) is under pressure as it extends a sharp selloff into Friday’s premarket session, building on steep...
📰
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
Findings underpin potential of Anavex’ lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy...
📰
Best Healthcare Stocks to Buy After the Market Pullback
They have the means to recover from recent setbacks.
📰
Best Healthcare Stocks to Buy After the Market Pullback
They have the means to recover from recent setbacks.
📰
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT
Participants using CARDAMYST in...
📰
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical...
Earnings Scheduled For March 20, 2026
Companies Reporting Before The Bell
• BitFuFu (NASDAQ:FUFU) is likely to report quarterly earnings at $0.01 per share on revenue of $105.15 million....
📰
Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today...
📰
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1...